Washington, D.C.-More seniors are enrolling in Medicare Advantage plans, particularly in the expanding number of more flexible "private fee-for-service" (PFFS) plans.
WASHINGTON, D.C.-More seniors are enrolling in Medicare Advantage plans, particularly in the expanding number of more flexible "private fee-for-service" (PFFS) plans. The Centers for Medicare and Medicaid Services (CMS) reported a 20% rise in MA plan members for 2006; about half of the growth is in PFFS plans, and the other half in HMOs and PPOs; local HMOs continue to dominate the MA program, with 5.4 million of nearly 7.5 million total MA enrollees.
PFFS plans are attractive to seniors because they don't limit beneficiaries to providers in a certain network. This also has made them more expensive than HMOs or PPOs, but now they can receive more attractive rates, particularly for serving Medicare patients in rural areas. PFFS plans thus are growing most noticeably in rural and other areas that previously did not attract MA plans because of difficulties contracting with the smaller number of physicians in these markets who often are reluctant to join MCO networks.
PFFS plans now serve more than 800,000 seniors, more than half of them in plans sponsored by Humana, according to an analysis by Avalere Health. This represents a jump from about 220,000 PFFS enrollees last December and just 20,000 three years ago. While Humana PFFS covers Medicare Part D drug benefits, seniors in such plans sponsored by UHC-Pacificare and WellPoint obtain drug benefits from separate Part D plans.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More